Point72 Asia Singapore Pte. Ltd. Sells 3,902 Shares of Humana Inc. (NYSE:HUM)

Point72 Asia Singapore Pte. Ltd. lessened its holdings in Humana Inc. (NYSE:HUM) by 86.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 587 shares of the insurance provider’s stock after selling 3,902 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Humana were worth $219,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. lifted its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in shares of Humana in the second quarter valued at about $35,000. Family Firm Inc. bought a new stake in Humana during the second quarter worth about $37,000. Hollencrest Capital Management acquired a new position in Humana during the second quarter valued at approximately $40,000. Finally, Riverview Trust Co bought a new position in Humana in the second quarter valued at approximately $44,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Up 0.3 %

Shares of HUM opened at $313.04 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $37.72 billion, a PE ratio of 19.49, a P/E/G ratio of 2.44 and a beta of 0.50. The firm’s 50 day moving average is $352.81 and its 200-day moving average is $344.87. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.94 EPS. Equities research analysts forecast that Humana Inc. will post 16.01 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 1.13%. Humana’s payout ratio is 22.04%.

Analyst Ratings Changes

Several equities research analysts have recently commented on HUM shares. Deutsche Bank Aktiengesellschaft increased their price objective on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. increased their price target on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Piper Sandler assumed coverage on shares of Humana in a research note on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective on the stock. Morgan Stanley started coverage on shares of Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price for the company. Finally, Robert W. Baird started coverage on Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price target on the stock. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $398.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.